April 16, 2024 – Talk Bio

Boehringer Ingelheim Leverages Late-Stage Pipeline for 25 New Launches over the Next Decade

1 year ago talkbio0Tagged Administration occupational activities, approvals, boehringer ingelheim, Decade, expansion, Heart failure, Jardiance, late-stage pipeline, launches, pipeline, reshuffle

Boehringer Ingelheim, Late-stage pipeline, 25 new launches, Decade, Jardiance, Heart failure approvals, Ofev, Pipeline expansion, Management reshuffle

Novartis’ Fabhalta (Iptacopan) Receives FDA Priority Review for IgA Nephropathy (IgAN) Treatment

1 year ago talkbio0Tagged Fabhalta, IGA Glomerulonephritis, Iptacopan, Novartis, Phase 3, Priority Review, United States Food and Drug Administration

Novartis, Fabhalta, Iptacopan, IgA Nephropathy (IgAN), FDA Priority Review, Phase 3 Data

Ultragenyx’s GTX-102 Shows Promising Results in Mid-Stage Angelman Syndrome Study, Pivotal Study on the Horizon

1 year ago talkbio0Tagged Angelman Syndrome, Antisense Oligonucleotides, Behavioral Improvement, Cognitive Improvement, Gross Motor Improvement, GTX-102, mid-stage study, Sleep Improvement, Ultragenyx

Ultragenyx, GTX-102, Angelman Syndrome, Mid-Stage Study, Pivotal Study, Antisense Oligonucleotide, Cognitive Improvement, Behavioral Improvement, Sleep Improvement, Gross Motor Improvement